summari report sale result
repres growth organ report sale result came
ahead estim
consensu due primarili fx howev organ
growth easili surpass estim
street expect also beat bottom-lin
report adj ep ahead
acceler three four divis medic devic
diagnost dx establish pharmaceut epd
nutrit growth declin sequenti part due time
benefit post healthi growth mid-single-digit
surprisingli med devic growth led way
organ sever busi deliv strong double-
electrophysiolog given strong start momentum
busi rais organ ex-fx acquisit sale
growth guidanc
adj ep guidanc
repres increas midpoint respect
rang regard guid organ sale growth
adj ep bracket consensu
addit strong print deliv two key messag
call compani remain confid icgm design
libr fda regulatori process track in-lin
expect expect sustain current level
chang estim lower sale
estim organ
respect larg due fx increas
adj ep estim report
maintain adj estim rais
price target base
all-around strong print report adjust ep
ahead consensu estim guidanc
rel model ep beat primarili
driven lower tax rate vs estim gross
margin opex mostli line
forecast total revenu organ ex-fx
acquisit vs estim compar consensu
estim total us sale
organ ou sale organ mostli in-
line forecast ou
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep continu
oper ep includ stj amo alr deal
compani data secur llc estim reuter
organ sale growth acceler three four divis nutrit sale
consensu estim organ growth slow
reflect deceler pediatr vs adult growth acceler
vs worth note abt nutrit busi saw time benefit
result soft exclud benefit growth would closer
level diagnost dx sale mostli in-lin consensu
forecast faster dx growth organ vs reflect improv growth point
rapid dx molecular dx growth soft due purchas pattern africa medic
devic sale miss consensu beat estim organ growth
improv epd establish pharmaceut sale
larg in-lin consensu forecast organ growth acceler
ex-fx
growth led med devic post anoth strong quarter med devic growth
organ acceler vs growth devic growth led diabet
organ heart failur organ structur heart organ diabet saw robust growth
behind continu adopt libr ou see heart failur driven
primarili strong heartmat growth strength structur heart led mitraclip
grew organ global busi post growth driven part recent fmr
function mitral regurgit indic ou mitraclip growth ex-fx show sequenti
improv vs ex-fx recal mitraclip growth europ impact mitra-fr
multipl busi grew double-digit pocket softnessparticularli
neuromodul rhythm manag vascular abt neuromodul nmd franchis declin
continu hinder execut issu relat compani spinal
cord stimul salesforc separ post declin organ growth cardiac
rhythm manag vascular grew organ aforement segment
dilut med-tech growth encourag busi show sequenti
anoth quarter robust libr growth confid fda approv libr incl
icgm provid updat on-going launch libr progress ou strong
adopt equat sale in-lin estim ou libr adopt
remain robust contribut also consist estim regard libr
said remain confid obtain regulatori approv includ icgm design manag
also note regulatori process track in-lin intern expect oper front
make signific invest expand libr manufactur capac support strong
patient demand manag said first wave addit manufactur capac come on-line
next coupl month steadi cadenc addit capac expans beyond
ask potenti long-term sale opportun libr call manag comment
expect libr reach sale reason time refer model ww libr sale
increas
top bottom-lin guidanc rais today call rais previou full-year
top bottom-lin guidanc compani expect organ sale growth
adjust fx acquisit wind-down nutrit compar abt previou
guidanc organ regard fx manag expect report sale headwind roughli
vs previous full-year move expect full-year gross
margin littl less reflect invest support libr alin expans
modestli lower prior guidanc expect sg spend
somewhat less sale respect expect full-year tax rate
vs prior bottom-lin rais adj ep guidanc
mid-point equat report growth
guidanc introduc guid organ sale growth look
top-lin guidanc busi epd expect grow mid high-singl digit nutrit expect
grow mid-singl digit abt legaci dx franchis expect grow high-singl digit
rapid diagnost alr expect grow low mid-singl digit med devic expect
grow high-singl digit manag expect fx advers impact
report sale bottom-lin guid adj ep bracket previou
price target
price target base ep estim risk target includ
slower growth key busi market delay stj alr integr slower margin
expect continu deliv double-digit underli ep growth mid high-singl digit
underli sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
 incom statement million except per good sold profit profit includ includ med-tech profit profit includ expens fx loss expens ep continu ep includ discontinu analysiscost good margin margin profit profit compani report secur llc estim medic technolog
